PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)
Authors' conclusion
The PERFECTRA study suggested that starting with baricitinib was superior over TNFi in achieving response at 12 weeks and resulted in improved outcomes across all studied clinical measures and PROMs throughout the study duration in these patients.
Study context
- Population
- b/tsDMARD-naïve rheumatoid arthritis (RA), disease duration ≤5 years, without contraindications to b/tsDMARD, after csDMARD failure to achieve disease control in a treat-to-target (T2T) setting
- Participants
- 199 participants
- Comparison
- Baricitinib strategy vs TNF-inhibitors (TNFi) strategy after csDMARD failure in a T2T setting
- Baricitinibn = 97
- TNFin = 102reference
- Primary endpoint
- ACR50 response (non-inferiority, then superiority, of baricitinib strategy)
- Follow-up
- 12 weeks
Methodological detailspragmatic, multicentre, real-life, treat-to-target, non-inferiority, with superiority testing
- Pragmatic
- Multicentre
- Real-life
- Treat-to-target
- Non-inferiority, with superiority testing
Primary result
As reported in the abstract
ACR50 response · week 12
Secondary outcomes
DAS28-CRP <2.6 · week 12
Secondary outcomes throughout the study
- Baricitinib strategy demonstrated comparable or better outcomes than TNFi strategy
Original publication
PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs. RMD Open. Published 30 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →